Nexletol
Utilized to target hypercholesterolaemia to mitigate cardiovascular risk.
Strengths: 180mg
Where to Check Availability
Medicine details
- Alternative names
Nilemdo
- Therapeutic class
Adenosine triphosphate-citrate lyase inhibitor
- Pharmacological class
Lipid-lowering agent
- Contraindications
hypersensitivity to bempedoic acid; pregnancy; breastfeeding
- Minor side effects
hyperuricaemia; muscle spasms; back pain; abdominal pain
- Moderate side effects
gout; anaemia; increased liver enzymes
- Serious side effects
tendon rupture — requires immediate medical attention
- Dosage forms
Film-coated tablet
- Administration route
Oral use
- Patient summary
Utilized to target hypercholesterolaemia to mitigate cardiovascular risk.
- Prescription status
POM
- Manufacturer
Daiichi Sankyo
- Onset Time
2–4 weeks
- Duration
Ongoing
- Storage instructions
Store below 30°C.
- Drug interactions
Simvastatin; Pravastatin
- Age restrictions
Not for use in children.
- Pregnancy and breastfeeding
Pregnancy: Contraindicated. Breastfeeding: Do not use during breastfeeding.
Precautions and warnings
monitor uric acid levels; caution in patients with history of gout; monitor for tendon rupture
Mechanism of action
Bempedoic acid inhibits ATP-citrate lyase, an enzyme involved in cholesterol biosynthesis in the liver, resulting in reduced LDL-cholesterol levels in the blood.
Nexletol
Utilized to target hypercholesterolaemia to mitigate cardiovascular risk.
Editorial Notes
- Active ingredient(s): Bempedoic Acid
- Listed indication(s): Primary Hypercholesterolaemia, Mixed Dyslipidaemia
Available option
- 60 tablets - 180 mg1473-180-mg-17698